WO2004032970A3 - Carriers attached to blood cells - Google Patents

Carriers attached to blood cells Download PDF

Info

Publication number
WO2004032970A3
WO2004032970A3 PCT/US2003/032502 US0332502W WO2004032970A3 WO 2004032970 A3 WO2004032970 A3 WO 2004032970A3 US 0332502 W US0332502 W US 0332502W WO 2004032970 A3 WO2004032970 A3 WO 2004032970A3
Authority
WO
WIPO (PCT)
Prior art keywords
carriers
circulation
blood cells
sustained
extended periods
Prior art date
Application number
PCT/US2003/032502
Other languages
French (fr)
Other versions
WO2004032970A2 (en
Inventor
Samir Mitragotri
Elizabeth Chambers
Original Assignee
Samir Mitragotri
Elizabeth Chambers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samir Mitragotri, Elizabeth Chambers filed Critical Samir Mitragotri
Priority to AU2003300043A priority Critical patent/AU2003300043A1/en
Publication of WO2004032970A2 publication Critical patent/WO2004032970A2/en
Publication of WO2004032970A3 publication Critical patent/WO2004032970A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The present invention is a method by which carriers can remain in vascular circulation for extended periods of time by binding to the outer membrane of red blood cells (RBCs). Freely circulating carriers are cleared from circulation within a few minutes to hours, depending on their size and surface characteristics. The adhesion between the RBC and carriers protects the carrier from vascular clearance by phagocytic cells. Sustained circulation of carriers is used for drug delivery. Alternatively, sustained carriers may also be used as contrast agents that circulate for extended periods of time and used for diagnostics.
PCT/US2003/032502 2002-10-10 2003-10-10 Carriers attached to blood cells WO2004032970A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003300043A AU2003300043A1 (en) 2002-10-10 2003-10-10 Carriers attached to blood cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41757602P 2002-10-10 2002-10-10
US60/417,576 2002-10-10

Publications (2)

Publication Number Publication Date
WO2004032970A2 WO2004032970A2 (en) 2004-04-22
WO2004032970A3 true WO2004032970A3 (en) 2004-06-03

Family

ID=32094040

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/032502 WO2004032970A2 (en) 2002-10-10 2003-10-10 Carriers attached to blood cells

Country Status (2)

Country Link
AU (1) AU2003300043A1 (en)
WO (1) WO2004032970A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0811856D0 (en) 2008-06-27 2008-07-30 Ucl Business Plc Magnetic microbubbles, methods of preparing them and their uses
EP3936122A1 (en) * 2008-11-24 2022-01-12 Massachusetts Institute Of Technology Methods and compositions for localized agent delivery
WO2015048498A2 (en) 2013-09-27 2015-04-02 Massachusetts Institute Of Technology Carrier-free biologically-active protein nanostructures
EP3334417A4 (en) 2015-08-12 2019-07-17 Massachusetts Institute of Technology Cell surface coupling of nanoparticles
CA3029813A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
US11524033B2 (en) 2017-09-05 2022-12-13 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
US20220323603A1 (en) * 2019-06-07 2022-10-13 President And Fellows Of Harvard College Compositions and methods relating to erythrocytes with adhered particles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3022278A1 (en) * 1979-06-13 1981-01-08 Ortho Diagnostics Polymer bound erythrocytes and stroma - attached by diazo gps., useful for separating pure blood group antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3022278A1 (en) * 1979-06-13 1981-01-08 Ortho Diagnostics Polymer bound erythrocytes and stroma - attached by diazo gps., useful for separating pure blood group antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DALE G L ET AL: "Erythrocytes attached to a wheat germ agglutinin coated surface display an altered phospholipid metabolism.", JOURNAL OF CELLULAR BIOCHEMISTRY. UNITED STATES SEP 1988, vol. 38, no. 1, September 1988 (1988-09-01), pages 1 - 11, XP002275402, ISSN: 0730-2312 *
KRANTZ A: "Red cell-mediated therapy: opportunities and challenges.", BLOOD CELLS, MOLECULES & DISEASES. UNITED STATES 1997, vol. 23, no. 1, 1997, pages 58 - 68, XP002275403, ISSN: 1079-9796 *
MUZYKANTOV V R ET AL: "Regulation of the complement-mediated elimination of red blood cells modified with biotin and streptavidin.", ANALYTICAL BIOCHEMISTRY. UNITED STATES 1 OCT 1996, vol. 241, no. 1, 1 October 1996 (1996-10-01), pages 109 - 119, XP002275404, ISSN: 0003-2697 *
SUZUKI T ET AL: "Biotinylated erythrocytes: in vivo survival and in vitro recovery", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 70, no. 3, September 1987 (1987-09-01), pages 791 - 795, XP002114026, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
AU2003300043A8 (en) 2004-05-04
WO2004032970A2 (en) 2004-04-22
AU2003300043A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
WO2005049593A3 (en) N-acylsulfonamide apoptosis promoters
WO2004075865A3 (en) Selective modulation of tlr-mediated biological activity
DE60333759D1 (en) CAPSULATED ACTIVE PARTICLES AND METHOD FOR THEIR PREPARATION AND USE
WO2007131128A3 (en) Systems and methods for producing multilayered particles, fibers and sprays and methods for administering the same
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
EP1479649A4 (en) Core-shell structure having controlled cavity inside and structure comprising the core-shell structure as component, and method for preparation thereof
WO2007051179A3 (en) Partially covered stent devices and methods of use
WO2004037861A3 (en) Neutralizing antibodies against gdf-8 and uses therefor
WO2003076490A8 (en) Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
WO2004047673A3 (en) Treatment of liver disease with active vitamin d compounds
WO2005021706A3 (en) Delivery of compounds with rehydrated blood cells
EP1579213A4 (en) Method of diagnosis,treatment and useful agents for conditions characterised by modulation in the level of activin beta c
WO2002078684A3 (en) Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
WO2004032970A3 (en) Carriers attached to blood cells
WO2005042727A3 (en) Methods of organ regeneration
WO2006065888A3 (en) Targeted iron chelator delivery system
WO2006060384A3 (en) Formulations of substituted benzoxazoles
WO2006004588A3 (en) Immunodynamic complexes and methods for using and preparing such complexes
WO2004072265A3 (en) Methods for monitoring drug activities in vivo
WO2003037168A3 (en) Methods and formulations for minimizing spasticity in blood vessel grafts
WO2006019978A3 (en) Compositions and methods for diagnosis and treatment of epilepsy
WO2000044398A3 (en) Methods for increasing circulating platelets for collection and cryopreservation using thrombopoietin compositions
AU2003229835A1 (en) Compounds, compositions and method for transporting cyclosporin molecules through the blood brain barrier
WO2000033887A3 (en) Methods and formulations for reducing circulating antibodies
WO2005042610A3 (en) Storage-stable polyurethane comprising silyl groups

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP